Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

The potential therapeutic use of some plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules (Basel, Switzerland) Switzerland), 2020-11, Vol.10 (11), p.1575
Main Authors: García-Gutiérrez, María S, Navarrete, Francisco, Gasparyan, Ani, Austrich-Olivares, Amaya, Sala, Francisco, Manzanares, Jorge
Format: Article
Language:English
Subjects:
Antidepressants
Antipsychotics
Anxiety
anxiety disorders
Cannabidiol
Cannabinoid CB1 receptors
Cannabinoid CB2 receptors
Cannabinoids
Cannabis
Clinical trials
Convulsions & seizures
depressive disorders
Dosage and administration
Drug abuse
Drug therapy
Drugs
Fatty acids
FDA approval
Marijuana
Mental depression
Mental disorders
Mental health
Neurogenesis
Patient outcomes
Pharmacodynamics
Pharmacokinetics
Post traumatic stress disorder
Psychoses
Psychosis
Psychotherapy
Psychotropic drugs
PTSD
Review
schizophrenia
Serotonin S1 receptors
Substance abuse treatment
Tetrahydrocannabinol
THC
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The potential therapeutic use of some plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute vs. chronic), and the route of administration. In addition, certain key targets have been related with these CBD pharmacological actions, including cannabinoid receptors (CB r and CB r), 5-HT receptor and neurogenesis factors. Preliminary clinical trials also support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile. These promising results support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders.
ISSN:2218-273X
2218-273X
DOI:10.3390/biom10111575